Restless Legs Syndrome: What the Research Actually Shows

An estimated 5 to 10 percent of adults meet criteria for restless legs syndrome, according to the large-scale REST study published by Allen and colleagues in 2005, which surveyed nearly 16,000 people across Europe and the United States. Roughly a quarter of those cases are moderate to severe enough to disrupt sleep at least twice a week. Yet RLS is still routinely mistaken for fidgeting, "growing pains," or anxiety, and the average patient waits years before getting a correct diagnosis. Here is what the iron, dopamine, and genetic research actually shows.

What Restless Legs Syndrome Actually Is

The International Restless Legs Syndrome Study Group's diagnostic criteria require four features: an urge to move the legs, usually accompanied by an uncomfortable sensation; symptoms that begin or worsen during rest; symptoms that are partially or fully relieved by movement; and symptoms that are worse in the evening or at night than during the day. That last criterion is what separates RLS from simple leg cramps or general restlessness — it has a distinct circadian pattern, and that pattern turns out to be a clue to the underlying mechanism rather than a coincidence.

The Iron Connection

The strongest and most clinically actionable finding in RLS research concerns brain iron, not blood iron. Cerebrospinal fluid studies by Earley and colleagues found reduced ferritin in the spinal fluid of RLS patients even when their serum ferritin looked normal on a standard blood panel, and autopsy work by Connor and colleagues in 2003 found measurably reduced iron staining in the substantia nigra — the same midbrain region central to dopamine production — in RLS patients compared to controls. This is why current clinical guidance from the RLS Foundation and sleep medicine societies sets the treatment threshold for iron supplementation at a serum ferritin below 75 ng/mL, well above the lab's usual "deficient" cutoff of around 15–30 ng/mL. A ferritin level that a general practitioner would call normal can still be low enough to drive RLS symptoms.

The Dopamine Pathway — and Its Trap

RLS symptoms respond to dopamine agonist medications, which is part of why dopamine dysfunction became the leading mechanistic theory, and it fits neatly with the iron finding since iron is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. It also helps explain the evening pattern: dopamine availability in the brain follows its own circadian rhythm and dips in the evening, which lines up with when RLS symptoms typically flare. But dopamine agonists carry a documented long-term risk called augmentation, described across multiple trials by Garcia-Borreguero and colleagues, in which symptoms paradoxically worsen, start earlier in the day, and spread to other body parts the longer someone takes the medication. That risk is significant enough that updated treatment guidelines now favor alpha-2-delta ligands such as gabapentin enacarbil as a first-line option for many patients rather than defaulting straight to dopamine agonists.

What the Genetics Show

A 2007 genome-wide association study by Winkelmann and colleagues, published in Nature Genetics, identified common variants in the MEIS1, BTBD9, and PTPRD genes strongly associated with RLS risk. The BTBD9 variant alone is carried by roughly half the general population, so it is not deterministic — it raises risk rather than guaranteeing the condition, consistent with RLS being a polygenic trait shaped by multiple small-effect variants interacting with iron status. Family-history studies estimate that 50 to 60 percent of people with primary RLS have a first-degree relative with the same condition, which is a useful diagnostic clue when symptoms are ambiguous.

What Actually Helps

Because low brain iron is the most consistently reproducible finding, checking serum ferritin before trying anything else is the evidence-based starting point — supplementing blindly without testing risks iron overload, which carries its own problems. When ferritin is under the 75 ng/mL threshold, a well-absorbed, non-constipating form such as Thorne's Iron Bisglycinate is easier to tolerate than standard ferrous sulfate, which has a higher dropout rate in trials due to gastrointestinal side effects. For the evening symptom flare itself, some clinicians use magnesium adjunctively alongside correcting iron status, and a bisglycinate form like Thorne's Magnesium Bisglycinate is well tolerated at bedtime, though the RLS-specific evidence for magnesium is thinner than the iron evidence and it should not replace a ferritin test. For non-drug relief, the Restiffic foot wrap is an FDA-cleared device specifically indicated for RLS that applies sustained, targeted pressure to two points on the foot, a mechanism thought to interrupt the neural signaling that produces the urge to move. Beyond supplementation and devices, avoiding known triggers matters: caffeine, alcohol, certain antihistamines, and some SSRIs and SNRIs are all associated with worsened symptoms in susceptible people, and moderate regular exercise reduces symptom severity in trials, though vigorous exercise too close to bedtime can backfire.

When to See a Doctor

Symptoms disrupting sleep more than twice a week are worth a clinical workup rather than indefinite self-management, both because a ferritin test is simple and because the augmentation risk with dopamine agonists means that treatment, when needed, is best sequenced correctly from the start rather than escalated informally.